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Chapter 1
General Introduction
The yield of cultivated crop plants is threatened by destruction by plant pathogens, 
especially when such crop plants are grown in large-scale monocultures. Because these crop
plants are all genetically identical, if one is susceptible to a pathogen, all will be. Thus plant 
diseases caused by plant pathogens are a serious agricultural problem worldwide.1 Indeed, 
plant pathogens are estimated to cause a 16% loss in the production of major crop plants
around the world.1 In order to meet the increasing food demands of the expanding human 
population, agricultural production must be increased; accordingly, the practice of crop 
protection plays a key role. Crop protection practices have been based on abundant increases 
in the use of synthetic pesticides, which are sometimes highly toxic to humans and non-target 
organisms and in some cases show a prolonged persistence in the environment.
Botrytis cinerea Pers. Fr. causes gray mold disease in more than 200 mostly dicotyledonous 
plant species and leads to serious losses in yield and quality in many crops, particularly 
vegetables and fruits.2 B. cinerea is difficult to control because of its variety of modes of 
attack, diverse inoculum sources, and survival strategy as both mycelia and conidia.2
Although chemical control has been used as a standard practice for many years, B. cinerea
possesses an ability to adapt quickly to chemical fungicides and to develop tolerant or 
resistant strains.3 For example, two benzimidazole-type compounds, benomyl and 
carbendazim, have been widely used against gray mold disease in the past but have been 
abandoned because of the development of widespread resistance to the compounds.4 This 
adaptive capacity of B. cinerea underscores the need for the continuous development of new 
chemical fungicides.
In addition, due to the many concerns over chemical fungicides (their toxicity to humans
and persistence in the environment, the rapid emergence of fungicide resistance, and the high 
cost of discovering, developing, and registering these chemicals), biological control agents 
(BCAs) have also been attracting considerable attention.5 In fact, many BCA formulations are 
already available for practical use.6 Among them, Bacillus-species-based BCAs are 
considered to have promise due to their safety, ubiquity in nature, and exhibition of high 
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thermal tolerance through the formation of resistant spores. Biological control by Bacillus sp. 
involves a number of mechanisms, such as competition for space and nutrition, antagonism,
and induction of systemic resistance.
Bacillus species biological control strains (mainly B. subtilis, B. amyloliquefaciens, and B.
cereus) are known to produce a wide variety of bioactive metabolites such as cyclic 
lipopeptides (iturins)7,8 and cyclic lipodepsipeptides (surfactins and fengycins or 
plipastatins),7,8 polyketides (bacillaenes, difficidin, oxidifficidin, and macrolactins),9,10
peptides (plantazolicins),11 and aminopolyols (zwittermicin A and kanosamine).12,13 Among 
these bioactive compounds, cyclic lipopeptides (iturins) and cyclic lipodepsipeptides 
(surfactins, and fengycins or plipastatins) have received much attention as key compounds in 
BCAs because they play an important role in colonization on the plant, show potent activities 
against a wide variety of microorganisms, and induce systemic resistance of plants.7,8,14,15
Iturins are cyclic lipopeptides produced by several strains of Bacillus species and show
antibiotic action against fungi, including plant pathogenic fungi. Iturin A,16-18 bacillomycins 
D,19 F,20 and Lc,21 bacillopeptins,22 and mycosubtilin23 are the main variants of the iturin 
family. Bacillomycin D homologues are cyclic lipopeptides containing seven D-amino acids 
and a E-amino fatty acid. The E-amino fatty acids vary from C14 to C16 in their carbon 
numbers, and possess normal-, iso-, or anteiso-terminal structures. Of these, the bacillomycin 
D homologues containing the normal-C14, iso-C15, and anteiso-C15 E-amino fatty acids are 
the predominant ones in bacillomycin D (Table 1-1).19,24-30
Surfactins are cyclic lipodepsipeptides produced by several strains of Bacillus species and
are well known to act as potent surface-active compounds. Generally, they contain seven 
D-amino acids and a E-hydroxy fatty acid. Standard surfactin possesses a heptapeptide moiety, 
L-Glu1-L-Leu2-D-Leu3-L-Val4-L-Asp5-D-Leu6-L-Leu7, linked by an ester bond to a 
(R)-E-hydroxy fatty acid.31-33 In addition to standard surfactin, [Ala4]surfactin,34,35 
[Leu4]surfactin,36 [Ile4]surfactin,36 [Val7]surfactin,37-40 [Ile7]surfactin,37,41-44 and 
halobacillin45,46 (or lichenysins)47,48 are the main variants (Table 1-2).
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To develop new and effective BCAs against gray mold disease, a screening search was 
performed, and Bacillus amyloliquefaciens SD-32 was isolated from a soil sample obtained in 
Japan (Figure 1-1). In order to gain insight into the mechanisms responsible for the biological 
control attained by B. amyloliquefaciens strain SD-32, the factors that are produced by the 
bacterium and contribute to the control of gray mold disease were identified, and their roles in 
the biological control system were clarified in this study.
This thesis is composed of four chapters. Chapter 2 deals with the isolation of antifungal 
compounds, an elucidation of their structures, and an assessment of their activities against
several plant pathogens, including B. cinerea. In chapter 3, the isolation of synergistic factors 
that enhance the activities of the antifungal compounds, the elucidation of their structures, and 
an evaluation of their effects in combination with the antifungal compounds are described. In 
addition, the mechanism of the synergism is discussed.
E-amino acid
1 2 3 4 5 6 7
Iturin A Asn Tyrb Asn Gln Pro Asn Ser n -C14, ai -C15, iso -C15, n -C15, iso -C16, n -C16, ai -C17
Bacillomycin D Asn Tyr Asn Pro Glu Ser Thr n -C14, ai -C15, iso -C15, iso -C16, n -C16
Bacillomycin F Asn Tyr Asn Gln Pro Asn Thr ai -C15, iso -C15, iso -C16, n -C16, ai -C17, iso -C17
Bacillomycin Lca Asn Tyr Asn Ser Glu Ser Thr n -C14, ai -C15, iso -C15, iso -C16, n -C16
Mycosubtilin Asn Tyr Asn Gln Pro Ser Asn iso -C16, n -C16, ai -C17, iso -C17
aor bacillopeptins; bunderline indicates D-form.
D-amino acids
Table 1-1. Structures of Lipopeptides from Bacillus species
E-OH-fatty acid
1 2 3 4 5 6 7
Surfactin Glu Leu Leub Val Asp Leu Leu ai -C13, iso -C13, n -C13, iso -C14, n -C14, ai -C15, iso -C15, n -C15, iso -C16, ai -C17
[Ala4]Surfactin Glu Leu Leu Ala Asp Leu Leu iso -C14, n -C14, ai -C15, iso -C15, n -C15
[Leu4]Surfactin Glu Leu Leu Leu Asp Leu Leu -
[Ile4]Surfactin Glu Leu Leu Ile Asp Leu Leu -
[Val7]Surfactin Glu Leu Leu Val Asp Leu Val ai -C13, iso -C14, n -C14, ai -C15
[Ile7]Surfactin Glu Leu Leu Val Asp Leu Ile iso -C14, n -C14, ai -C15, iso -C15
Halobacillina Gln Leu Leu Val Asp Leu Ile -
aor lichenysins; bunderline indicates D-form.
Table 1-2. Structures of Lipodepsipeptides from Bacillus species
D-amino acids
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Figure 1-1. (A) Dual culture of Bacillus amyloliquefaciens SD-32 with Botrytis cinerea on a
PDA plate. (B) B. amyloliquefaciens SD-32 on a cucumber leaf. The scale bar 
indicates 5 Pm.
A                            B
Botrytis 
cinerea
Bacillus 
amyloliquefaciens SD-32
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Chapter 2
Isolation of Bacillomycin D Homologues from Bacillus amyloliquefaciens
SD-32 and Their Antifungal Activities against Plant Pathogens
2.1. Introducction
Botrytis cinerea Pers. Fr. is a pathogen of gray mold diseases in many fruit, vegetable, and 
ornamental crops and causes serious losses worldwide.1 Although chemical fungicides have
been used for many years to control the pathogen, the ability of B. cinerea to adapt quickly to 
new chemicals by developing its resistance always creates the need for developing new 
fungicides.2 With increasing concern regarding fungicide resistance of pathogens,
environmental impact, and food safety of the chemical fungicides, biological control has
attracted considerable attention.
In this context, a screening search was performed to develop effective biological control 
agents against gray mold disease and Bacillus amyloliquefaciens SD-32 showing strong 
antagonistic activity against B. cinerea was isolated from a soil sample obtained in Japan. To 
clarify the mechanisms of the biological control by B. amyloliquefaciens strain SD-32, the 
factors, which contribute to control gray mold disease, produced by the bacterium were
identified and their roles in the biological control system were evaluated. The identification 
and evaluation of the factors in SD-32 responsible for controlling gray mold disease could 
contribute to a better understanding of the molecular basis of this biological control system.
Using an in vitro antifungal activity-guided purification, four antifungal compounds, 1-4
(Figure 2-1), were isolated from its fermentation broth. In this chapter, I describe the isolation 
of these compounds, the elucidation of their structures, and their activities against some plant 
pathogens including B. cinerea.
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Figure 2-1. Structures of compounds 1-4.
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2.2. Materials and Methods
General Experimental Procedures. The solvents and reagents used in this study were 
purchased from Sigma-Aldrich, St. Louis, MO, USA, unless otherwise noted. NMR spectra 
were measured with Bruker Avance II 800US2, Bruker Avance II 600, and Bruker DRX500
systems (Bruker Daltonics, Billerica, MA, USA). The spectra for compounds 1-4 were 
acquired in pyridine-d5 (GH 7.19; GC 123.5) at room temperature. HR-ESI-MS spectra were
obtained with a Waters Micromass LCT Premier XE (Waters, Milford, MA, USA), and 
HR-FAB-MS spectra were obtained with a JEOL JMS-700 spectrometer (JEOL, Tokyo, 
Japan). Preparative HPLC and HPLC analyses were performed with a Waters Alliance 
system.
Microorganisms. Soil samples collected in Ibaraki prefecture, Japan, were suspended in 
sterilized water and vortexed. The supernatants were serially diluted with sterilized water and 
spread on nutrient agar plates (15 x 90 mm). The SODWHVZHUHLQFXEDWHGDWÛ&IRU h in 
darkness, and 500 colonies were transferred to other nutrient agar plates. Bacteria thus 
isolated were tested for their antifungal activity against a phytopathogenic fungus, Botrytis
cinerea Persoon MAFF 744071. PCR amplification of the 16S rRNA gene of strain SD-32
with universal forward (5’-AGAGTTTGATCCTGGCTCAG-3’) and reverse 
(5’-GGCTACCTTGTTACGACTT-3’) primers was carried out. The 16S sequence for SD-32
was deposited in GenBank (accession no. AB853319).
Isolation of Compounds 1-4. Strain SD-32 ZDVJURZQDWÛ&ZLWKUSPVKDNLQJIRU
64 h in 500 mL flasks containing liquid medium (50 mL/flask, total 800 mL) composed of 
maltose (80 g/L), soybean powder (80 g/L; J-OIL MILLS, Tokyo, Japan), yeast extract (10
g/L; Becton, Dickinson and Co., Franklin Lakes, NJ, USA), MgSO4·7H2O (2 g/L), CaCl2 (2 
g/L), K2HPO4 (1 g/L), FeSO4·7H2O (0.1 g/L), MnSO4·5H2O (0.1 g/L), and H2O adjusted 
pH 7.0 by Na2CO3. Antifungal metabolites were extracted from the culture filtrate (750 mL) 
with 1 L of EtOAc three times after adjustment of the pH to 4.0 with HCl. The EtOAc
solution was dehydrated over anhydrous Na2SO4 and concentrated to dryness to afford an
extract (3.8 g). The extract was dissolved in H2O, and the pH of the solution was adjusted to 
7.0. The solution was purified with solid-phase extraction (Oasis HLB 35 cc LP Extraction 
Cartridge, Waters) eluted stepwise with 50 mL each of 0, 20, 40, 60, 80, and 100% (v/v) 
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MeOH in H2O. The antifungal activity of each fraction was determined by the paper-disk
method using B. cinerea as the test organism on a potato dextrose agar (PDA, Becton, 
Dickinson and Co.) plate at 20 Û&IRUGD\V7KHDFWLYHIUDFWLRQVHOXWHGwith 60-80% MeOH
in H2O were combined and concentrated to dryness. The concentrate was subjected to
Sephadex LH-20 column chromatography with MeOH. The active fractions were pooled and 
evaporated to dryness to afford a residue (0.80 g). The residue was further purified by 
preparative HPLC (XBridge C18, 250 x 10 mm) eluted with 45% (v/v) CH3CN-H2O
containing 0.1% TFA at a flow rate of 4.7 P/PLQDWÛ&DQG absorbance at 205 nm was 
measured to afford the active compounds 1 (23 mg), 2 (92 mg), 3 (120 mg), and 4 (56 mg).
Amino Acid Analysis. Compound 3 (1 mg) ZDVK\GURO\]HGZLWK1+&ODWÛ&IRU
h, and the hydrolysate was dried with N2. The amino acids were analyzed using the Shimadzu 
Prominence Amino Acid Analysis System (Shimadzu Corp., Tokyo, Japan) by postcolumn 
fluorescence derivatization with o-phthalaldehyde (OPA) / N-acetylcysteine as the reaction 
reagent.
N-Bromosuccinimide Cleavage and Edman Degradation. Compound 3 (2.5 mg) was 
dissolved in 0.5 mL of 70% aqueous AcOH. N-Bromosuccinimide3 (2.5 mg) was added, and 
the solution was allowed to stand for 1 h at room temperature. Three drops of formic acid 
were added to the solution to terminate the reaction. The open-up fragment of compound 3
was purified by preparative HPLC (XBridge C18, 250 x 4.6 mm) eluted with 50% (v/v) 
CH3CN-H2O containing 0.1% TFA at a flow rate of 1.P/PLQDWÛ&DQGabsorbance at 
205 nm was measured. The N-terminal amino acid sequence of the fragment was determined 
by Edman degradation using the Shimadzu Protein Sequencer PPSQ-23A.
Matrix-Associated Laser Desorption Ionization Time of Flight (MALDI-TOF) MS/MS 
Analysis. MALDI-TOF MS/MS data were obtained with a Shimadzu AXIMA Resonance 
using a 337.1 nm nitrogen laser for desorption and ionization. 2,5-Dihydroxybenzoic acid (10 
mg/mL) in 50% (v/v) CH3CN-H2O containing 0.1% TFA was used as the matrix solution. 
Positive-ion detection and reflectron mode were used.
Absolute Configuration of D-Amino Acid. Compound 3 (1 mg) was hydrolyzed with 0.5 
ml of 6 1+&ODWÛ&IRUK and dried with N2. To the hydrolysate was added 100 PL of 
H2O, 200 PL of 1% FDAA (Marfey’s reagent)4 in acetone, and 40 PL of 1 M NaHCO3. The 
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mixture was kept DWÛ&IRUKDQGPL of 2 M HCl was added to terminate the reaction. 
The reaction mixture was analyzed by HPLC equipped with a reverse-phase column (XBridge 
C18, 250 x 4.6 mm) eluted with a linear gradient of 10% to 50% (v/v) CH3CN-H2O
containing 0.1% TFA in 45 min at a flow rate of 1.0 mL/min, 4Û&DQGabsorbance at 340
nm was measured. Derivatives of standard L- and D-amino acids were co-injected. To
determine the absolute configuration of Asn1 and Asn2, two tripeptides, 
NH2-L-Asp-D-Tyr-D-Asp and NH2-D-Asp-D-Tyr-L-Asp, were used as standard peptides 
(Sigma-Aldrich). Compound 3 (3 mg) was hydrolyzed in 0.5 mL of 3 1+&ODWÛ&IRUK
and dried with N2. To the hydrolysate was added 100PL of H2O, and the hydrolysate 
solution was analyzed by HPLC equipped with a phenyl column (XBridge Phenyl, 250 x 4.6
mm), eluted with 5% (v/v) CH3CN-H2O containing 0.1% TFA at a flow rate of 1.0 mL/min, 
 Û& DQG absorbance at 280 nm was measured. Two standard tripeptides,
NH2-L-Asp-D-Tyr-D-Asp and NH2-D-Asp-D-Tyr-L-Asp, were eluted at 8.2 and 7.3 min,
respectively.
Absolute Configuration of E-Amino Fatty Acid. A ȕ-amino fatty acid of compound 3 was 
produced by the K\GURO\VLV P/RI1+&O  Û&KRI FRPSRXQG3 (10 mg) and 
extraction with FKORURIRUP 'LQLWURSKHQ\ODWLRQ RI WKH ȕ-amino fatty acid was carried out 
according to Sanger’s procedure.5 The Dnp derivative thus obtained was treated with 
p-methoxyaniline, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, and 
1-hydroxybenzotriazole in methylene chloride. The reaction products were purified by 
preparative HPLC using a column (XBridge C18, 250 x 4.6 mm) eluted with 90% (v/v) 
CH3CN-H2O containing 0.1% TFA at a flow rate of 1P/PLQDWÛ&DQG absorbance at 
340 nm was measured to yield the dinitrophenyl-p-methoxyaniline derivative (< 1.0 mg). The 
structure was confirmed by mass ([M+H]+, 557.4) and 1H-NMR (CDCl3) spectra. The amount 
of the derivative was determined to be 0.41 mg by a calculation based on H value at A347 in 
the literature.6 The CD spectrum of the derivative was compared to that in the literature.6 CD 
(c 8.4 x 10-5 M, MeOH) Omax ¨H) 262 (+4.29), 300 (+0.54), 330 (+0.77), 400 (–1.82) nm.
In Vitro Assay against Plant Pathogens. We obtained the following from the National 
Institute of Agrobiological Science, Tsukuba, Japan: Botrytis cinerea Persoon MAFF 744071, 
Rhizoctonia solani J. G. Kuehn MAFF 305219, Fusarium oxysporum Schlechtendahl MAFF 
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410171, Pyricularia grisea (Cooke) Saccardo MAFF 101583, Alternaria alternata (Fries) 
Keissler MAFF 731001, Botryosphaeria berengeriana De Notaris f. sp. pyricola Koganezawa 
et Sakuma MAFF 645002, Didymella bryoniae (Fuckel) Rehm MAFF 235932, and Pythium 
aphanidermatum (Edson) Fitzpatrick MAFF 239200. The following strains were obtained
from Biological Resource Center (NBRC), National Institute of Technology and Evaluation,
Chiba, Japan: Colletotrichum acutatum Simmonds NBRC 32849, Monilinia fructicola
(Winter) Honey NBRC 30451, Penicillium expansum Link ex S.F. Gray NBRC 5453, and 
Sclerotinia sclerotiorum (Libert) de Bary NBRC 4876. Fusarium graminearum Schwabe 
ARC 2075-1 was supplied from NARO Agricultural Research Center, Tsukuba, Japan. The 
DMSO solution (60 PL) of the each compound was added to 6 mL of PDA KHOGDWÛ&7KH
agar medium was poured onto a 60 mm plate. Each compound was tested at concentrations of 
2.5, 5.0, 10, 20, 40, and 80 Pg/mL. A PDA disk (5 mm in diameter) with mycelia of each test 
pathogen was placed on each plate containing a compound. The pathogens were incubated at 
 Û& IRU  GD\V B. cinerea, D. bryoniae, and S. sclerotiorum), 2 days (R. solani, P. 
aphanidermatum, F. graminearum, B. berengeriana, and M. fructicola), 2.5 days (F.
oxysporum), 3 days (P. expansum and C. acutatum), 4 days (A. alternata), and 5 days (P.
grisea). The pathogens growing on PDA (6 mL) containing 60PL of DMSO were used as 
controls. All experiments were performed in triplicate. IC50 values (median inhibitory 
concentrations) were calculated using the inhibition rate of mycelial growth. That rate was 
calculated as
Inhibition rate of mycelial growth (%) = (1 – Da/Db) x 100
where Da is the diameter of the pathogen colony in the plate containing a test compound and 
Db is the diameter of the colony in the control plate. The results were expressed as IC50 (mean,
PM (95% confidential interval)).
Leaf-Disk Assay Using Cucumber Cotyledon and Botrytis cinerea. Cucumber seeds 
(Cucumis stativus L., Sagami-Hanjiro) were planted in 12 cm pots containing artificial soil 
and grown in the greenhouse at 16 to 23 Û& without supplemental lighting. The cotyledons 
were collected from 3-week-old plants. The test compound was dissolved in an appropriate 
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amount of phosphate buffer (40 mM, pH 7.2), and 50 PL of the solution was applied to a 
paper disk (8 mm in diameter, thick type, Advantec Toyo Kaisha, Ltd., Tokyo, Japan) on the 
cucumber cotyledon. For the control, only phosphate buffer was applied. Then the paper disks
on the leaves were inoculated with 50 PL of B. cinerea spore suspension (2 x 104/mL) 
containing 0.2% (w/v) yeast extract and 2 % (w/v) sucrose. Each compound was tested at 
final concentrations of 10, 20, 30, 40, 60, and 80 PM. The leaves were kept in a humidity 
chamber (relative humidity >95%) at 20 Û& for 4 days in darkness. The experiment was 
repeated four times. The inhibition rate of B. cinerea infection was calculated as
Inhibition rate of infection (%) = (1 – Dc/Dd) x 100
where Dc is the diameter of the infection zone in the leaf with a test compound and Dd is the 
diameter of the infection zone in the control leaf. The results were expressed as inhibition rate 
(mean % ±SD).
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2.3. Results and Discussion
Isolation of Compounds 1-4 from Bacillus amyloliquefaciens SD-32. In my screening 
search, SD-32, a bacterium isolated from soil, was found to have strong antifungal activity 
against plant pathogen Botrytis cinerea. The PCR product of its 16S rRNA gene was 
sequenced to give a 1472 bp sequence followed by a BLAST similarity search; it was 
identified as Bacillus amyloliquefaciens (99.9% similarity with B. amyloliquefaciens type 
strain). SD-32 was cultured in a medium (800 mL) composed of maltose, soybean powder, 
yeast extract, and some minerals at 30Û& for 64 h. Antifungal activity-guided purification of 
the EtOAc extract of the culture filtrate with solid-phase extraction, gel filtration, and 
preparative HPLC afforded compounds 1 (23 mg), 2 (92 mg), 3 (120 mg), and 4 (56 mg) as 
white amorphous powders. The HPLC profile at the final step of purification is shown in 
Figure 2-2.
      
Figure 2-2. Preparative HPLC of compounds 1-4 in the active fractions after Sephadex 
LH-20 column chromatography.
Structures of Compounds 1-4. Since compound 3 was most abundant in the culture broth,
we elucidated its structure first. Compound 3 gave an [M+H]+ peak at m/z 1073.5902 (Calcd 
for C51H81N10O15, 1073.5883) in HR-ESI-MS. Six D-amino acids, Asp, Tyr, Glu, Pro, Ser,
and Thr, were found in a 2:1:1:1:1:1 ratio in an amino-acid analysis of the hydrolysate.
Because the 1H-NMR spectrum of compound 3 in DMSO-d6 showed peaks due to a couple of 
conformers, pyridine-d5 was used as NMR solvent. The 1H-NMR data for compound 3 (Table 
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2-1 and Figure S1) indicated the presence of 11 amide protons (GH 9.66-7.80) and 7 D-protons 
(GH 5.39-4.72, partially overlapped) of amino acid residues of a peptide, a p-substituted 
benzene ring (GH 7.47 d, 7.06 d, 2H each), a long methylene chain (GH 1.20-1.15), and three 
terminal methyl groups (GH 1.34 d, 0.82 t, and 0.82 d, each 3H). The 13C-NMR data for
compound 3 (Table 2-2 and Figure S2) exhibited 49 signals, including 11 carbonyl groups (GC
), a p-substituted benzene (GC 157.5, 1C; 131.3, 2C; 128.6, 1C; 116.1, 2C), 
methylene carbons (GC 63.5-26.1), and three methyl carbons (GC 20.8, 19.3 and 11.5). Thus 
compound 3 was deduced to be anteiso-C17 bacillomycin D, a cyclic lipopeptide consisting of 
two Asn, one Tyr, one Pro, one Glu, one Ser, and one 7KUUHVLGXHVDQGDȕ-amino acid with a 
-(CH2)10CH(CH3)CH2CH3 group as a side chain from the 1H-1H COSY, HSQC, HMBC, and 
NOESY data shown in Figure 2-3 and Figures S3-S6, and also by considering the molecular 
formula. To confirm this, chemical and MALDI-TOF MS/MS analyses were conducted as 
follows. Compound 3 was cleaved at the C-terminus of the Tyr residue by 
N-bromosuccinimide3 and the cleaved product (oxidized form of Tyr with 2 moles of Br, 
molecular mass 1246) was purified by preparative HPLC. The fragment was analyzed by 
Edman degradation and yielded the following sequence: NH2-Asn-Pro-Glu-Ser-Thr-X
(Figure 2-4A). Compound 3 was also analyzed by MALDI-TOF MS/MS to afford the 
sequence information as shown in Figure 2-4B. These results confirmed that the structure of 
compound 3 was anteiso-C17 bacillomycin D.
The absolute configurations of D-amino acids in compound 3 were determined by treatment 
of the hydrolysate with Marfey’s reagent4 and HPLC analysis of the derivatives. The 
hydrolysate was shown to contain L-Asp, D-Tyr, D-Asp, L-Pro, L-Glu, D-Ser, and L-Thr. There 
is no ambiguity in the absolute configuration of the five amino acids other than Asn (in the 
form of the corresponding Asp). The absolute configurations of the two Asn were determined 
by HPLC comparison of the tripeptide in the partial hydrolysate of compound 3 with two
synthesized tripeptides, NH2-L-Asp-D-Tyr-D-Asp and NH2-D-Asp-D-Tyr-L-Asp. The 
existence of NH2-L-Asp-D-Tyr-D-Asp in the hydrolysate finally allowed us to establish the 
amino acid sequence, NH2-L-Asn-D-Tyr-D-Asn-L-Pro-L-Glu-D-Ser-L-Thr of compound 3.
To determine the absolute configuration of C3 in the ȕ-amino fatty acid, the ȕ-amino fatty 
acid was isolated from the hydrolysate of compound 3 and modified with 
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dinitrofluorobenzene and p-methoxyaniline (Figure 2-4C). The CD spectra of the 
dinitrophenyl-p-methoxyaniline derivative was similar to that of the derivative of iturinic 
acid,6 indicating apparently that the ȕ-amino fatty acid of compound 3 had an R-configuration,
the same as iturinic acid.
The HR-MS of compounds 1, 2, and 4 showed their [M+H]+ ion peaks at m/z 1045.5552
(HR-FAB-MS; Calcd for C49H77N10O15, 1045.5570), 1059.5756 (HR-ESI-MS; Calcd for 
C50H79N10O15, 1059.5726), and 1073.5876 (HR-ESI-MS; Calcd for C51H81N10O15,
1073.5883), respectively. A series of NMR spectral analyses (Figures S7-S16) revealed that 
compounds 1, 2, and 4 had the same amino acid sequence as compound 3, except for the side 
chain structures of the E-amino fatty acids. The 1H-NMR and 13C-NMR spectra of compounds 
1, 2, and 4 showed the presence of the -(CH2)9CH(CH3)2, -(CH2)10CH(CH3)2, and 
-(CH2)11CH(CH3)2 groups, respectively. Thus compounds 1, 2, and 4 were determined to be
iso-C15, iso-C16, and iso-C17 bacillomycin D, respectively.
Compounds 1 and 2 are known,7 and 3 and 4 are new. Compounds 3 and 4 have anteiso-
and iso-C17 ȕ-amino fatty acids, and seven D-amino acids with the same chiral sequence,
LDDLLDL, as the iturin family. This is the first report to establish the absolute structure of 
bacillomycin D. The metabolites assumed to be anteiso-C17 and iso-C17 bacillomycin D (3
and 4) were previously detected in mass spectrometric analyses of extracts from Bacillus
species by Koumoutsi et al.,8 Ramarathnam et al.,9 Athukorala et al.,10 and Liu et al.,11
although their chemical structures were not determined. The lipid moieties of compounds 3
(anteiso-C17) and 4 (iso-C17) were previously reported in iturin A,12, 13 bacillomycin F,14 and 
mycosubtilin,15 and the reported contents of C17 homologues in iturin A, bacillomycin F, and 
mycosubtilin were 3, 39, and 61%, respectively. In case of bacillomycin D, Peypoux et al.7
reported percentages of each homologue (C14, C15, and C16) in bacillomycin D were 48, 35, 
and 12 %, respectively, and did not mention C17 homologues. Hourdou et al.16 showed 
contents of each homologue (C14, C15, C16, and C17) in bacillomycin D were 48, 30, 22, and 
0 %, respectively. It is noteworthy that the content of the C17 bacillomycin D homologues was 
very high (60%) in the present study.
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       
Figure 2-3. Key COSY, HMBC, and NOESY correlations detected for compound 3.
 
Figure 2-4. Reaction schemes for chemical analyses and MALDI-TOF MS/MS analysis: (A) 
N-bromosuccinimide cleavage of compound 3 followed by Edman degradation; 
(B) MALDI-TOF MS/MS analysis of compound 3; (C) preparation of Dnp-p-MA 
derivative of E-amino fatty acid from compound 3 to determine the absolute
configuration of E-amino fatty acid.
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moiety position
1 2 3 4
L-Asn1 1 5.31m 5.27m 5.27m 5.27m
2 3.08m, 3.08dd (15.3, 5.4), 3.08dd (15.4, 5.6), 3.07dd (15.4, 5.5), 
3.03mb 3.02mb 3.02mb 3.01mb
1-NH 9.17brs 9.04brs 9.03brs 9.02brs
3-NH2 8.45brsc, 7.89brs 8.38brsc, 7.81brs 8.37brsc, 7.80brs 8.37brsc, 7.80brs
D-Tyr 5 5.40m 5.32m 5.32m 5.32m
6 3.72dd (13.6, 4.6),
3.41dd (13.6, 10.0)
3.72m,
3.40m
3.72dd (13.8, 4.7),
3.40dd (13.8, 9.8)
3.72dd (13.7, 4.6),
3.39dd (13.7, 10.0)
8, 12 7.47d (8.1) 7.47d (8.2) 7.47d (8.3) 7.47d (8.1)
9, 11 7.06d (8.1) 7.06d (8.2) 7.06d (8.3) 7.06d (8.1)
5-NH 9.68brs 9.66brs 9.66brs 9.66brs
D-Asn2 14 5.55m 5.38m 5.39m 5.39m
15 3.58dd (15.7, 8.6),
3.18dd (15.7, 4.8)
3.57dd (15.5, 9.1),
3.18dd (15.5, 4.8)
3.57dd (15.6, 9.2),
3.18dd (15.6, 5.1)
3.57dd (15.6, 9.3),
3.18dd (15.6, 5.0)
14-NH 9.00brs 8.96brs 8.95brs 8.94brs
16-NH2 8.62brs, 7.97brs 8.56brs, 7.90brs 8.55brs, 7.89brs 8.55brs, 7.88brs
L-Pro 18 4.73m 4.73dd (8.0, 5.3) 4.72dd (8.2, 5.4) 4.72dd (7.9, 5.6)
19 2.10m, 2.08m 2.10m, 2.08m 2.11m, 2.08m 2.10m, 2.07m
20 1.84m, 1.61m 1.86m, 1.65m 1.86m, 1.65m 1.86m, 1.65m
21 4.22m, 4.00m 4.27m, 4.04m 4.26m, 4.03m 4.26m, 4.03m
L-Glu 23 4.87md 4.87md 4.87md 4.87md
24 2.78m, 2.61me 2.79m, 2.62me 2.79m, 2.62me 2.79m,  2.62me
25 3.03mb, 2.94m 3.03mb, 2.95m 3.03mb, 2.95m 3.03mb, 2.95m
23-NH 8.45brsc 8.38brsc 8.36brsc 8.36brsc
D-Ser 28 4.92md 4.89md 4.89md 4.89md
29 4.40m,
4.33m
4.38dd (11.4, 3.3),
4.33dd (11.4, 3.5)
4.38dd (11.3, 3.2),
4.33dd (11.3, 3.5)
4.38dd (11.4, 3.0),
4.33dd (11.4, 3.2)
28-NH 8.84brs 8.74brs 8.74brs 8.75brs
L-Thr 31 4.92md 4.89md 4.89md 4.89md
32 4.94md 4.95m 4.95m 4.95m
33 1.34d (6.0) 1.34d (6.3) 1.34d (6.4) 1.34d (6.2)
31-NH 8.23brs 8.16brs 8.15brs 8.14brs
D-Ǆ-AA 35 4.62m 4.62m 4.61m 4.61m
36 2.64me, 2.45m 2.62me, 2.43m 2.62me, 2.43m 2.63me, 2.43m
38 1.57m, 1.43mf 1.55m, 1.45mf 1.56m, 1.45m 1.56m, 1.45mf
39 1.30m 1.30m 1.28m 1.30m
40 1.18-1.12g 1.19-1.14g 1.20-1.15g 1.21-1.15g
41 1.18-1.12g 1.19-1.14g 1.20-1.15g 1.21-1.15g
42 1.18-1.12g 1.19-1.14g 1.20-1.15g 1.21-1.15g
43 1.18-1.12g 1.19-1.14g 1.20-1.15g 1.21-1.15g
44 1.18-1.12g 1.19-1.14g 1.20-1.15g 1.21-1.15g
45 1.18-1.12g 1.19-1.14g 1.20-1.15g 1.21-1.15g
46 1.08m 1.19-1.14g 1.20-1.15g 1.21-1.15g
47 1.43mf 1.11m 1.24mf, 1.08m 1.21-1.15g
48 0.82d (6.6) 1.43mf 1.24mf 1.11m
49 0.82d (6.6) 0.83d (6.7) 0.82d (6.3) 1.45mf
50 0.83d (6.7) 1.24mf 0.83d (6.6)
51 0.82t (7.4) 0.83d (6.6)
35-NH 8.20brs 8.12brs 8.11brs 8.11brs
a Compound 1, 500MHz; 2, 600MHz; 3 and 4, 800MHz. b, c, d, e, f, g Overlapped in each column.
Table 2-1. 1H NMR Data for Compounds 1-4 in Pyridine-d 5a
G+J  in Hz)
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moiety position
1 2 3 4
L-Asn1 1 52.8 52.9 52.9 52.9
2 37.1 37.1 37.1 37.1
3 172.7b 172.7b 172.7b 172.7b
4 173.0b 172.9b 172.9b 172.9b
D-Tyr 5 55.9 55.9 55.9 55.9
6 36.4 36.5 36.5 36.4
7 128.7 128.6 128.6 128.7
8, 12 131.3 131.3 131.3 131.3
9, 11 116.1 116.1 116.1 116.1
10 157.4 157.5 157.5 157.5
13 173.6c 173.7c 173.7c 173.7c
D-Asn2 14 50.2 50.3 50.3 50.3
15 37.8 37.8 37.8 37.8
16 172.5b 172.5b 172.6b 172.6b
17 172.9b 172.7b 172.7b 172.7b
L-Pro 18 62.0 62.2 62.1 62.1
19 29.6d 29.8d 29.7d 29.6d
20 25.0 25.0 25.0 25.0
21 48.5 48.6 48.6 48.5
22 172.5b 172.4b 172.4b 172.4b
L-Glu 23 55.3 55.4 55.4 55.4
24 27.7 27.7 27.7 27.7
25 31.7 31.7 31.7 31.7
26 175.6 175.5 175.5 175.5
27 173.6c 173.8c 173.8c 173.7c
D-Ser 28 59.4 59.3 59.3 59.3
29 63.4 63.6 63.5 63.5
30 171.7 171.7 171.7 171.7
L-Thr 31 57.8 57.9 57.9 57.9
32 66.4 66.2 66.2 66.2
33 20.7 20.8 20.8 20.8
34 171.1 171.1 171.1 171.1
D-Ǆ-AA 35 47.5 47.4 47.4 47.4
36 41.9 42.0 42.0 42.0
37 173.2b 173.2b 173.2b 173.2b
38 35.7 35.7 35.7 35.7
39 26.1 26.1 26.1 26.1
40 29.6d 29.6d 29.6d 29.6d
41 29.7d 29.9d 29.7d 29.7d
42 29.8d 29.9d 29.9d 29.9d
43 29.9d 29.9d 29.9d 29.9d
44 29.9d 30.0d 30.0d 30.0d
45 30.2d 30.2d 30.0d 30.0d
46 39.2 30.5d 30.3d 30.0d
47 28.1 39.2 36.8 30.2d
48 22.7 28.2 34.6 39.2
49 22.7 22.7 19.3 28.1
50 22.7 27.4 22.7
51 11.5 22.7
b, c, d Assignments may be interchanged in each column.
a Compound 1, 125 MHz; 2, 150 MHz; 3 and 4, 200 MHz.
Table 2-2. 13C NMR Chemical Shifts of Compounds 1-4 in Pyridine-d 5a
G C
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Activities of Compounds 1-4 against Plant Pathogens. The activities of compounds 1-4
were evaluated against 13 plant pathogens in PDA medium, and the results are shown in Table 
2-3. The table reveals that the activities of compounds 3 and 4 (anteiso- and iso-C17) were 
almost the same against all fungi tested and were stronger than those of compounds 1 and 2;
compound 1 was the weakest. Compounds 1-4 inhibited the growth of all fungi tested, and B.
berengeriana, B. cinerea, P. grisea, D. bryoniae, S. sclerotiorum, and M. fructicola were the 
most sensitive to the compounds. By contrast, the oomycete P. aphanidermatum was not 
inhibited at all by any of the compounds. The activity of iturin family lipopeptides is 
attributed to their membrane-disruptive property through a direct lipopeptide-sterols 
interaction.17 The oomycetes do not synthesize sterols,18 and thus are assumed to be 
insensitive to bacillomycin D homologues.
The structure-antifungal activity relationships of iturin A,19 bacillomycin Lc,20 and 
bacillopeptins21 have been studied. The activity of iturin A is directly related to the lipophilic 
side chain of its E-amino fatty acid; the activity increased with the number of carbon atoms in 
the E-amino fatty acid (C16 > C15 > C14). The same results were obtained for bacillomycin Lc
and bacillopeptins. Recently, Tabbene et al.22 investigated bacillomycin D-like compounds
and showed that their anti-Candida activity increased in the order of the side chain length: C16
> C15 > C14. This result for bacillomycin D showed that the order of activity against plant 
pathogens was C17 > C16 > C15; the activity of bacillomycin D increased with side chain 
length until C17. Recently, it was reported that mycosubtilin interacts preferentially with 
ergosterol compared to the other classes of lipids and that the presence of ergosterol makes it 
easier to insert the lipopeptide into the membrane.23 The E-amino fatty acid with 17 carbon 
atoms in bacillomycin D is assumed to be the best-fitting molecule for hydrophobic 
interactions with the sterols in the membrane.
Finally, leaf-disk assay using cucumber cotyledon and B. cinerea was conducted to clarify 
the potential effect of bacillomycin D against gray mold disease. The result is shown in Table 
2-4 and Figure 2-5. Compounds 1-4 at concentrations of 80, 40, 30, and 30 PM, respectively,
inhibited completely the B. cinerea infection in the cucumber leaf. 
The present study demonstrates that strain SD-32 is unique because it produced a higher 
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contents of the C17 bacillomycin D homologues than other strains reported previously. The
result of in vitro antifungal assay showed that the activities of C17 bacillomycin D 
homologues are much stronger than the known C15 and C16 homologues, and also from the 
result of the cucumber leaf-disk assay it was pointed out that the C17 bacillomycin D 
homologues can control gray mold disease. These indicate that this unique strain, SD-32,
must be a potential promising resource for the biological control of plant disease.
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Figure 2-5. Leaf-disk assay using cucumber cotyledon and Botrytis cinerea.
Table 2-3. Activities of Compounds 1-4 against Plant Pathogens
plant pathogen 1 2 3 4
Botryosphaeria berengeriana  MAFF 645002 -a 5.0 (4.4-5.4) 3.7 (3.4-4.2) 4.0 (3.8-4.5)
Botrytis cinerea  MAFF 744071 28.2 (26.3-30.2) 8.6 (7.8-9.3) 4.2 (3.9-4.6) 4.1 (3.4-4.7)
Pyricularia grisea  MAFF 101583 - 6.6 (5.9-7.3) 4.3 (3.9-4.8) 4.5 (4.1-5.0)
Didymella bryoniae  MAFF 235932 - 7.6 (6.8-8.6) 4.7 (4.1-5.2) 4.6 (4.0-5.2)
Sclerotinia sclerotiorum NBRC 4876 - 6.9 (6.1-7.6) 4.9 (4.3-5.4) 4.6 (4.0-5.1)
Monilinia fructicola  NBRC 30451 - 7.3 (6.5-8.2) 5.0 (4.3-5.8) 4.8 (4.3-5.6)
Rhizoctonia solani  MAFF 305219 59.0 (51.9-69.6) 12.8 (11.9-14.0) 6.5 (5.8-7.3) 7.9 (7.1-8.9)
Colletotrichum acuatum  NBRC 32849 30.5 (25.7-36.7) 14.6 (12.3-17.7) 10.6 (9.0-13.0) 10.4 (8.8-12.8)
Penicillum expansum  NBRC 5453 29.0 (23.8-35.7) 13.0 (10.5-17.5) 10.9 (8.6-14.9) 10.9 (8.9-14.1)
Fusarium oxysporum  MAFF 410171 43.9 (38.6-51.0) 18.9 (15.5-25.5) 14.1 (11.8-17.9) 12.2 (10.6-14.4)
Fusarium gramunearum  ARC 2075-1 - 17.4 (15.2-20.1) 11.2 (9.5-13.0) 12.8 (11.0-14.9)
Alternaria alternata  MAFF 731001 - 20.0 (15.9-28.4) 14.6 (12.1-18.6) 15.3 (13.3-18.1)
Pythium aphanidermatum  MAFF 239200 >40 >40 >40 >40
aNot tested.
IC50 (mean, PM (95% confidential interval))
Table 2-4. Leaf-Disk Assay Using Cucumber Cotyledon and Botrytis cinerea
compd 10 PM 20 PM 30 PM 40 PM 60 PM 80 PM
1 3.8 ± 9.0 15.9 ± 12.5 7.5 ± 26.6 -14.2 ± 11.0 19.5 ± 19.6 100
2 18.3 ± 12.3 29.1 ± 25.8 77.2 ± 22.9 100 100 100
3 3.8 ± 15.2 19.5 ± 21.3 100 100 100 100
4 21.9 ± 28.9 20.7 ± 5.4 100 100 100 100
inhibition rate (%) ± SD (n  = 4)
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Chapter 3
Isolation of [Ile7]Surfactin Homologues from B. amyloliquefaciens SD-32
and Their Synergistic Effects in Combination with Bacillomycin D in
Suppression of Gray Mold Disease
3.1. Introduction
In chapter 2, I described Bacillus amyloliquefaciens SD-32 obtained from a soil sample in 
Japan as a promising and effective agent against gray mold disease, and two new compounds,
anteiso- and iso-C17 bacillomycin D in its fermentation broth. The strain SD-32 is quite 
different from other strains previously reported with respect to its production of C17
bacillomycin D homologues as major metabolites. The activities of C17 bacillomycin D 
homologues against B. cinerea were stronger than those of the known C15 and C16
homologues both in vitro and in vivo. These data indicate that the strain is a potentially 
promising resource for the biological control of gray mold disease, and indeed, the culture 
supernatant of this strain possesses a strong suppressive effect on gray mold disease in vivo.
However, bacillomycin D homologues did not account for all of the activity in the culture 
supernatant of this strain, suggesting that other factors effective against gray mold disease 
were also present. The identification of all factors in SD-32 that are effective in controlling
gray mold disease could contribute to a better understanding of the molecular basis of this 
biological control system.
In the course of purifying the fractions exhibiting synergistic activity with bacillomycin D
in control of gray mold disease, five cyclic lipodepsipeptides (5-9) were found in the culture 
supernatant of this strain (Figure 3-1). The synergistic effects of compounds 5-9 with 
bacillomycin D in the suppression of gray mold disease were evaluated using an in vivo
cucumber leaf-disk assay.
In this chapter, the factors that possess synergistic effects with bacillomycin D and 
contribute to control gray mold disease are described.
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Figure 3-1. Structures of compounds 5-9.
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3.2. Materials and Methods
General Experimental Procedures. The solvents and reagents used in this study were 
purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise noted. NMR spectra 
were measured with Bruker Avance II 600 and Bruker Ascend 400 systems (Bruker Daltonics, 
Billerica, MA, USA). The spectra for compounds 5-9 were acquired in DMSO-d6 (GH 2.49;
GC 39.5) at room temperature. HR-FAB-MS was obtained with a JEOL JMS-700 
spectrometer (JEOL, Tokyo, Japan). Preparative HPLC and HPLC analyses were performed 
with a Waters Alliance system (Waters, Milford, MA, USA).
Microorganisms. Isolation and identification of the Bacillus amyloliquefaciens strain 
SD-32 were described in the previous chapter.
Partial Purification of Factors Effective against Gray Mold Disease. Strain SD-32 was 
JURZQDWÛ&ZLWKVKDNLQJat 150 rpm for 64 h in a 500 mL flask containing 50 mL of liquid 
medium, composed of maltose (80 g/L), soybean powder (80 g/L; J-OIL MILLS, Tokyo, 
Japan), yeast extract (10 g/L; Becton, Dickinson and Co., Franklin Lakes, NJ, USA), 
MgSO4·7H2O (2 g/L), CaCl2 (2 g/L), K2HPO4 (1 g/L), FeSO4·7H2O (0.1 g/L), 
MnSO4·5H2O (0.1 g/L), and H2O adjusted pH 7.0 by Na2CO3. The culture supernatant (44 
mL) was extracted with 50 mL of EtOAc three times after adjusting the pH (pH 4.0) with HCl.
The EtOAc solution was dried over anhydrous Na2SO4 and concentrated in vacuo. The dry 
extract was dissolved in H2O, and the pH of the solution was adjusted to 7.0. The solution 
was purified with solid-phase extraction (C18-SPE, Oasis HLB 6g/35 cc LP Extraction 
Cartridge; Waters) eluted stepwise with 50 mL each of 0, 20, 40, 60, 80, and 100% (v/v) 
CH3CN-H2O containing 0.1% TFA. Each fraction was evaporated in vacuo. The residues of 
each fraction were dissolved in 40 mL of phosphate buffer (40 mM, pH 7.2) and the each 
solution was evaluated in an in vivo cucumber leaf-disk assay.
HPLC Analyses of Culture Supernatant and C18-SPE Fractions. The amount of 
bacillomycin D in culture supernatant was determined by HPLC (XBridge C18, 250 x 4.6
mm; Waters), eluted with linear gradient 20 to 100% (v/v) CH3CN-H2O containing 0.1% 
TFA for 20 min at a flow rate of 1.0 P/PLQDWÛ&DQGGHWHFWHGby absorbance at 205 nm.
The purified anteiso-C17 bacillomycin D was used as standard bacillomycin D. The C18-SPE 
fractions were analyzed under the same condition.
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Isolation of Compounds 5-9. Strain SD-ZDVJURZQDWÛ&ZLWKVKDNLQJat 150 rpm 
for 64 h in 500 mL flasks containing medium, which was the same as the case of partial 
purification (50 mL/flask, 1.6 L in total). The metabolites were extracted from the culture 
supernatant (1.5 L) with 2 L of EtOAc three times after adjusting the pH (pH 4.0) with HCl. 
The EtOAc solution was dried over anhydrous Na2SO4 and concentrated to dryness to afford 
a crude extract (4.6 g). This extract was dissolved in H2O, and the pH of the solution was 
adjusted to 7.0. The solution was purified by SPE (C18-SPE, Oasis HLB 6g/35 cc LP 
Extraction Cartridge) eluted stepwise with 50 mL each of 0, 20, 40, 60, 70, 80, 90, and 100% 
(v/v) CH3CN-H2O containing 0.1% TFA. The fractions eluted with 70-80% CH3CN-H2O
were combined and concentrated to dryness to afford a residue (0.35 g). The residue was 
further purified by preparative HPLC (XBridge C18, 250 x 10 mm), eluted with 70% (v/v) 
CH3CN-H22FRQWDLQLQJ7)$DWD IORZUDWHRIP/PLQDW Û&DQGGHWHFWHGby 
absorbance at 205 nm, to afford the active compounds 5 (17 mg), 6 (16 mg), 7 (79 mg), 8 (15
mg), and 9 (10 mg). The purified compounds 5-9 were analyzed by HPLC (XBridge C18, 250 
x 4.6 mm), eluted with 70% (v/v) CH3CN-H2O containing 0.1% TFA at a flow rate of 1.0
P/PLQDWÛ&DQGGHWHFWHGby absorbance at 205 nm.
Amino Acid Analysis. Amino acid analysis of compound 7 was conducted according to the 
method described in the previous chapter.
Matrix-Associated Laser Desorption Ionization Time of Flight (MALDI-TOF) MS/MS 
analysis. MALDI-TOF MS/MS analysis of compound 7 was performed according to the 
method described in the previous chapter.
Determination of Lactone Linkage. Determination of the lactone linkage position in
compound 7 was conducted according to the method reported by Naruse et al.1 Compound 7
(10 mg) was treated with LiBH4 (50 mg) in dry THF (5 mL) under reflux for 6 h. The reaction 
mixture was diluted with H2O and extracted with EtOAc at pH 2.0. The extract was dried 
with N2 and hydrolyzed with 6 N HCl at 110Û& for 20 h. Amino acids in the hydrolysate were 
analyzed according to the method described in the previous chapter.
Absolute Configuration of D-Amino Acids. Absolute configurations of the D-amino acids, 
except for the three Leu residues, of compound 7 were determined according to Marfey’s
method.2 The experimental details were described in the previous chapter.
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To determine the absolute configurations of Leu2 and Leu3, four tripeptides, 
NH2-L-Leu-L-Leu-L-Val, NH2-D-Leu-D-Leu-L-Val, NH2-D-Leu-L-Leu-L-Val, and 
NH2-L-Leu-D-Leu-L-Val, were used as standard peptides (Sigma-Aldrich). Compound 7 (3 
mg) was hydrolyzed in 0.5 mL of 12N HCl/AcOH (2:1, v/v) at 60 Û&IRU6 h, and dried with 
N2. To the hydrolysate was added 150PL of 25% (v/v) CH3CN-H2O, and then the solution 
was analyzed by LC/MS system (Prominence HPLC system, Shimadzu Corp., Tokyo, Japan;
and 3200 QTRAP, AB SCIEX, Framingham, MA, USA) equipped with a reverse-phase
column (Zorbax Extend C18, 150 x 2.1 mm; Agilent Technologies, Santa Clara, CA, USA), 
eluted with a linear gradient of 10 to 30% (v/v) CH3CN-H2O containing 0.1% formic acid in 
30 min at a flow rate of 0.2 mL/min, 3 Û& Four standard tripeptides, 
NH2-L-Leu-L-Leu-L-Val, NH2-D-Leu-D-Leu-L-Val, NH2-D-Leu-L-Leu-L-Val, and 
NH2-L-Leu-D-Leu-L-Val, were eluted at 11.4, 15.5, 16.9, and 23.0 min, respectively.
To determine the absolute configuration of Leu6, two tripeptides, NH2-L-Asp-L-Leu-L-Ile 
and NH2-L-Asp-D-Leu-L-Ile, were used as standard peptides (Sigma-Aldrich). The 
hydrolysate solution of compound 7 described above was analyzed by LC/MS system 
(Prominence HPLC system and 3200 QTRAP) equipped with a reverse-phase column 
(Zorbax Extend C18, 150 x 2.1 mm), eluted with a linear gradient of 5 to 95% (v/v) 
CH3CN-H2O containing 0.1% formic acid in 30 min at a flow rate of 0.2 mL/min, 3Û&Two
standard tripeptides, NH2-L-Asp-L-Leu-L-Ile and NH2-L-Asp-D-Leu-L-Ile were eluted at 10.4
and 11.9 min, respectively.
Absolute Configuration of the E-Hydroxy Fatty Acid. Mosher’s method was used to 
determine the absolute stereochemistry of the E-hydroxy fatty acid residue.3,4 Compound 7
(10 mg) was hydrolyzed in 1.0 mL of 6 N HCl at 110 Û& for 15 h. The hydrolysate was diluted 
with 5 mL of H2O, extracted with 5 mL of CHCl3 three times, and dried by N2. The residue 
was dissolved with 1 mL of CH2Cl2-MeOH (3:1, v/v) and then 0.1 mL of TMS-diazomethane
(Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) was added to the solution. The solution 
was allowed to stand at room temperature for 30 min and the reaction was terminated by 
addition of 10% acetic acid in MeOH. The solution was dried by N2 and the residue was 
dissolved in 0.5 mL of dry CH2Cl2 and mixed with 5.0 mg of (dimethylamino)pyridine, 2.8 
PL of triethylamine, and 3.8 PL of (+)-MTPA chloride (Tokyo Chemical Industry). The 
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solution was allowed to stand at room temperature for 4 h. 3-[(Dimethylamino)propyl]amine 
(1.9 PL) was added, and after standing for 10 min, the solution was poured into 10 mL of 0.6 
N HCl and extracted with 10 mL of EtOAc three times. The EtOAc extract was washed twice 
with 10 mL of 0.1 M NaHCO3 and evaporated, affording (R)-MTPA ester of E-hydroxy fatty 
acid methyl ester. (S)-MTPA ester of E-hydroxy fatty acid methyl ester was prepared 
according to the same procedure using (–)-MTPA chloride in place of (+)-MTPA chloride.
In Vivo Cucumber Leaf-Disk Assay against B. cinerea. Cucumber seeds (Cucumis 
stativus L., Sagami-Hanjiro) were planted in 12 cm pots containing artificial soil and grown in 
the greenhouse at 16 to 23 Û& without supplemental lighting. The cotyledons were collected 
from 3-week-old plants. The test compound (or supernatant) was dissolved in an appropriate 
amount of phosphate buffer (40 mM, pH 7.2), and 50 PL of the solution was applied to a 
paper disk (8 mm in diameter, thick type, Advantec Toyo Kaisha, Ltd., Tokyo, Japan) on the 
cucumber cotyledon. For the control, only phosphate buffer was applied. Then the paper disks 
on the leaves were inoculated with 50 PL of B. cinerea spore suspension (2 x 104/mL) 
containing 0.2% (w/v) yeast extract and 2 % (w/v) sucrose. The leaves were kept in a 
humidity chamber (RH >95%) at 20 Û& for 4 days in darkness. The experiment was repeated 
four times. Inhibition rate of B. cinerea infection was calculated as
Inhibition rate of infection (%) = (1 – Da/Db) x 100
where Da is the diameter of the infection zone in the leaf with a test compound and Db is the 
diameter of the infection zone in the control leaf. The results were expressed as inhibition rate 
(mean % ±SD). The assay was observed under a stereomicroscope SZX7 (Olympus Co., 
Tokyo, Japan).
In Vitro Mycelial Growth Inhibition Assay. The assay procedure and calculation methods 
were described in the previous chapter. The combined action of two compounds was 
evaluated using Abbott’s formula.5 The expected efficacy of a mixture of two compounds, 
expressed as Eexp, can be predicted by Abbott’s formula:
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Eexp = c + d – (cd/100)
c and d are the control levels given by the single compounds. Synergistic interaction was 
determined to be present in the mixture when the ratio of the experimentally observed 
efficacy of the mixture (Eobs) to the expected one (Eexp) was > 1.
In Vitro Conidial Germination Inhibition Assay. The compound was dissolved in an 
appropriate amount of phosphate buffer (40 mM, pH 7.2), and 100 PL of the solution was 
applied to a tissue culture plate (a 96-well flat-bottom plate with a low evaporation lid; 
Becton, Dickinson and Co.). For the control, only phosphate buffer was applied. The solution 
in each well of the tissue culture plate was supplied with 100 PL of B. cinerea conidia (2 x 
104/mL) containing 0.2% (w/v) yeast extract and 2% (w/v) sucrose. Compound 7 and 
anteiso-C14 bacillomycin D were tested at final concentrations of 20 and 4 PM, respectively.
The tissue culture plate was kept at 20 Û& for 20 h in darkness. The germination of conidia 
was observed under a light microscope CK2 (Olympus Co.). The assay was done in triplicate.
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3.3. Results and Discussion
Contribution of Bacillomycin D to the Suppressive Activity of the Culture 
Supernatant against Gray Mold Disease. Strain SD-32 produces C15-17 bacillomycin D
homologues, which are powerful antifungal lipopeptides. To clarify the actual contribution of 
bacillomycin D to the suppressive activity of the culture supernatant against gray mold 
disease, I subjected the culture supernatant to an in vivo cucumber leaf-disk assay and also 
measured the bacillomycin D concentration in the culture supernatant. A 20-fold dilution of 
the culture supernatant was sufficient to inhibit the infection of B. cinerea completely, and the 
total concentration of bacillomycin D homologues in this solution was 11 PM (Figure 3-2A). 
In this assay, 30 PM of bacillomycin D was needed to completely control B. cinerea (Figure 
3-2B), suggesting that factors other than bacillomycin D contributed to the effect of the 
culture supernatant on gray mold disease. These data prompted us to perform the following 
experiments.
Contribution of Synergistic Factors to the Control of Gray Mold Disease. The culture 
supernatant from SD-32 culture was partially purified with EtOAc extraction followed by 
solid-phase extraction (C18-SPE) and the activities of each fraction were evaluated. The 60%
CH3CN fraction of C18-SPE showed a suppressive effect against gray mold disease in the in
vivo assay (Figure 3-2C), and this fraction contained bacillomycin D homologues (Figure 
3-2E). Fractions other than the 60% CH3CN fraction showed no suppressive effects (Figure 
3-2C); interestingly, however, the 80% CH3CN fraction enhanced the suppressive effect of 
the 60% fraction 2-fold (Figure 3-2D), suggesting a synergistic effect of the 80% CH3CN 
fraction with bacillomycin D homologues. The 80% CH3CN fraction did not contain 
bacillomycin D, but did contain several unidentified metabolites (Figure 3-2E). These data led 
us to isolate and identify the synergistic factors in the 80% fraction.
Isolation of Compounds 5-9 from Bacillus amyloliquefaciens SD-32. SD-32 was 
cultured in a medium (1.6 L) composed of maltose, soybean powder, yeast extract, and some 
minerals at 30Û& for 64 h. Synergistic activity-guided purification of the EtOAc extract of the 
culture supernatant with solid-phase extraction and preparative HPLC afforded compounds 5
(17 mg), 6 (16 mg), 7 (79 mg), 8 (15 mg), and 9 (10 mg) as white amorphous powders (each 
purity, >90%). The elution profile at the final HPLC purification step is shown in Figure 3-2F.
41 
 
The chromatograms of each purified compound are shown in Figure 3-2G.
 
Figure 3-2. In vivo cucumber leaf-disk assay of the culture supernatant and C18-SPE (Oasis 
HLB) fractions and HPLC of the metabolites. (A) In vivo cucumber leaf-disk 
assay of the culture supernatant (n = 4). The values above each bar indicate the
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bacillomycin D concentrations. (B) In vivo cucumber leaf-disk assay of the 
purified anteiso-C17 bacillomycin D (n = 4). (C) In vivo cucumber leaf-disk assay 
of the SPE fractions. Gray mold disease was completely inhibited on the leaves in 
the dashed box. (D) In vivo cucumber leaf-disk assay of the SPE fractions 
combined with a 60% CH3CN fraction. (E) HPLC analyses of the fractions 
obtained from partial purification. Chromatograms of the 60 and 80% CH3CN 
fractions were overlaid: black line, 60% CH3CN fraction containing bacillomycin 
D; red line, 80% CH3CN fraction containing unknown metabolites. (F) Elution 
profile at the final HPLC purification step of compounds 5-9. Each peak was 
fractionated, pooled, and then freeze-dried. (G) HPLC analyses of purified 
compounds. Each chromatogram was overlaid: red line, compound 5 (0.4 mg/mL); 
blue line, 6 (0.4 mg/mL); black line, 7 (0.5 mg/mL); sky blue line, 8 (0.5 mg/mL); 
purple line, 9 (0.5 mg/mL).
Structures of Compounds 5-9. Compound 7 was the most abundant in the culture broth,
and therefore its structure was elucidated first. Compound 7 gave an [M+Na]+ peak at m/z
1044.6602 (calcd for C52H91N7O13Na, 1044.6573) in HR-FAB-MS. Five D-amino acids, Leu,
Glu, Val, Asp, and Ile, were found in a 3:0.9:0.9:0.9:0.7 ratio in an amino acid analysis of the 
hydrolysate. The 1H-NMR data for compound 7 (Table 3-1 and Figure S17) indicated the 
presence of seven amide protons (GH 8.34-7.68) and seven D-protons (GH 4.53-4.08, partially 
overlapped) of amino acid residues of the peptide. The 13C-NMR (Table 3-2 and Figure S18)
and HSQC data (Figure S20) for compound 7 exhibited 50 signals (GC 172.1 and 22.5; 2C 
each), including 9 carbonyl (GC 174.1-169.4GC 172.1, 2C), methylene (GC 41.6-24.5), and 11
methyl carbon signals (GC 23.1-11.1; GC 22.5, 2C). On the basis of the 1H-1H COSY, HSQC, 
HMBC, NOESY data (Figure 3-3A and Figures S19-S22), and the molecular formula, 
compound 7 was deduced to be iso-C14 [Ile7]surfactin, a cyclic depsipeptide consisting of 
three Leu residues, one Glu, one Val, one Asp, and one Ile residue, and a E-hydroxy fatty acid 
with a -(CH2)8CH(CH3)2 group as a side chain. To obtain the sequence information, 
compound 7 was analyzed by MALDI-TOF MS/MS to afford the sequence shown in Figure 
3-3B, which corresponded with that of iso-C14 [Ile7]surfactin. Then, to determine the location 
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of the lactone linkage, compound 7 was reduced with LiBH4 in THF and the amino acid 
composition of the product was analyzed. The reaction product lacked the Ile residue (Figure 
3-3C; the intact and reduced compound 7 afforded Leu, Val, Glu, Asp, and Ile in the ratios 
3:0.9:0.9:0.9:0.7 and 3:1:0.8:0.9:0.03, respectively), indicating that the lactone linkage was 
between the carboxyl group of Ile and the E-hydroxy group of the fatty acid. From these 
results compound 7 was determined to be iso-C14 [Ile7]surfactin (Figure 3-1).
The absolute configurations of D-amino acids in compound 7 were determined by treatment 
of the hydrolysate with Marfey’s reagent2 and HPLC analyses of the derivatives. The 
hydrolysate was shown to contain L-Glu, L-Val, L-Asp, L-Ile, L-Leu, and D-Leu. There is no 
ambiguity in the absolute configuration of the four amino acids other than Leu. The absolute 
configurations of the Leu2 and Leu3 were determined by LC/MS comparison of the tripeptide 
in the products from the partial hydrolysis of compound 7 with four synthesized tripeptides, 
NH2-L-Leu-L-Leu-L-Val, NH2-D-Leu-D-Leu-L-Val, NH2-D-Leu-L-Leu-L-Val, and 
NH2-L-Leu-D-Leu-L-Val. The existence of NH2-L-Leu-D-Leu-L-Val in the hydrolysate 
allowed us to determine the absolute configuration of Leu2 and Leu3 to be L and D,
respectively. The absolute configuration of the Leu6 was also determined by LC/MS
comparison of the tripeptide in the products from the partial hydrolysis of compound 7 with 
two synthesized tripeptides, NH2-L-Asp-L-Leu-L-Ile and NH2-L-Asp-D-Leu-L-Ile. The 
existence of L-Asp-D-Leu-L-Ile in the hydrolysate finally established the amino acid sequence,
NH2-L-Glu-L-Leu2-D-Leu3-L-Val-L-Asp-D-Leu6-L-Ile. The absolute configuration at C-3 of 
the fatty acid part of compound 7 was determined according to the Mosher’s method3,4 as 
shown in Figure 3-3D. 1H NMR spectra of the (R)-MTPA and (S)-MTPA esters of E-hydroxy 
fatty acid methyl ester were measured, respectively, and from the ¨G(S - R) values the absolute 
configuration of C-3 was determined to be R.
The HR-FAB-MS of compounds 5 and 6 showed their [M+H]+ ion peaks at m/z 1008.6581
(calcd for C51H90N7O13, 1008.6596) and 1008.6575 (calcd for C51H90N7O13, 1008.6596),
respectively. The HR-FAB-MS of compounds 8 and 9 showed their [M+Na]+ ion peaks at m/z
1058.6741 (calcd for C53H93N7O13Na, 1058.6729) and 1058.6727 (calcd for C53H93N7O13Na,
1058.6729), respectively. A series of NMR spectral analyses (Figures S23-S38) revealed that 
compounds 5, 6, 8, and 9 had the same amino acid sequence as compound 7 but differed from 
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compound 7 with respect to the structure of their E-hydroxy fatty acids. The 1H-NMR and 
13C-NMR spectra of compounds 5, 6, 8, and 9 showed the presence of the 
-(CH2)6CH(CH3)CH2CH3, -(CH2)7CH(CH3)2, -(CH2)8CH(CH3)CH2CH3, and 
-(CH2)9CH(CH3)2 groups, respectively. Thus, compounds 5, 6, 8, and 9 were determined to 
be anteiso-C13, iso-C13, anteiso-C15, and iso-C15 [Ile7]surfactin, respectively (Figure 3-1).

Figure 3-3. 2D-NMR, MS/MS, and chemical analyses of compound 7: (A) key COSY and 
HMBC correlations detected for compound 7; (B) MALDI-TOF MS/MS analysis
of compound 7; (C) determination of the lactone linkage position of compound 7;
(D) determination of the absolute structure of C-3 in E-hydroxy fatty acid obtained 
from compound 7. ¨G(S - R) values (in ppm) of derivatives synthesized according to
a Mosher’s method.
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Compounds 7, 8, and 9 are known,6-10 and 5 and 6 are new. Compounds 5 and 6 have 
anteiso- and iso-C13 3-hydroxy fatty acids, and seven D-amino acids with the same chiral 
sequence, LLDLLDL, as the surfactin family. [Ile7]surfactin homologues have been reported 
to be produced by Bacillus subtilis6,8-10 and B. licheniformis.7 The present study shows that B. 
amyloliquefaciens strain SD-32 is a producer of [Ile7]surfactin homologues. Recently, Tang et 
al. reported the 13C NMR data (in DMSO) of anteiso-C15 [Ile7]surfactin,10 and their data were 
identical to my 13C NMR data for compound 8, except for the chemical shift of DCH of Ile7
(GC 56.5, present study; GC 50.7, reported). A metabolite from Bacillus subtilis OKB 105 was
characterized as C13 [Ile7]surfactin from NMR and MS data by Kowall et al.9 although its 
chemical structure was not unambiguously determined.
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moiety position
5 6 7 8 9
L-Glu 1 4.18mb 4.18mb 4.18mb 4.18mb 4.18mb
2 1.92mc, 1.77md 1.92mc, 1.76md 1.91mc, 1.76m 1.91mc, 1.76md 1.91mc, 1.76md
3 2.19m 2.17m 2.19m 2.19m 2.19m
1-NH 7.84d (6.2) 7.84d (6.4) 7.84d (6.5) 7.84d (6.6) 7.83d (6.6)
L-Leu2 6 4.15mb 4.15mb 4.16mb 4.15mb 4.15mb
7 1.53me 1.53me 1.53md 1.53me 1.53me
8 1.50me 1.50me 1.50md 1.50me 1.50me
9 0.86m 0.86m 0.86m 0.86m 0.86m
10 0.86m 0.86m 0.86m 0.86m 0.86m
6-NH 8.00d (5.1) 8.03d (5.3) 8.04d (5.2) 8.03d (5.6) 8.02d (5.4)
D-Leu3 12 4.17mb 4.16mb 4.17mb 4.16mb 4.17mb
13 1.53me 1.53me 1.53md 1.53me 1.53me
14 1.50me 1.53me 1.50md 1.50me 1.50me
15 0.81mf 0.82df (6.5) 0.83de (6.5) 0.81mf 0.83df (6.6)
16 0.81mf 0.82df (6.5) 0.83de (6.5) 0.81mf 0.83df (6.6)
12-NH 8.29d (7.0) 8.32d (7.0) 8.34d (7.1) 8.32d (7.1) 8.31d (7.3)
L-Val 18 4.07m 4.07m 4.08m 4.07m 4.08m
19 1.95mc 1.95mc 1.93mc 1.93mc 1.94mc
20 0.81mf 0.82df (6.5) 0.83de (6.5) 0.81mf 0.83df (6.6)
21 0.75d (6.5) 0.74d (6.5) 0.75d (6.6) 0.74d (6.4) 0.75d (6.6)
18-NH 7.73d (8.5) 7.75d (8.4) 7.76d (8.3) 7.75d (8.3) 7.75d (8.5)
L-Asp 23 4.49mg 4.50mg 4.52mf 4.50mg 4.50mg
24 2.68dd (16.4, 4.3), 2.68dd (16.6, 4.3), 2.68dd (16.6, 4.6), 2.68dd (16.5, 4.2), 2.69dd (16.6, 4.7),
2.57dd (16.4, 8.7) 2.57dd (16.6, 8.7) 2.58dd (16.6, 8.9) 2.57dd (16.5, 8.7) 2.57dd (16.6, 8.6)
23-NH 8.17d (7.1) 8.18d (7.2) 8.18d (7.1) 8.18d (7.2) 8.17d (7.2)
D-Leu6 27 4.51mg 4.51mg 4.53mf 4.51mg 4.52mg
28 1.41mh, 1.38mh 1.41mh, 1.37mh 1.43mg, 1.38m 1.43mh, 1.38mh 1.44mh, 1.39mh
29 1.50me 1.50me 1.50md 1.50me 1.50me
30 0.81mf 0.82df (6.5) 0.83de (6.5) 0.81mf 0.83df (6.6)
31 0.81mf 0.82df (6.5) 0.83de (6.5) 0.81mf 0.83df (6.6)
27-NH 7.66d (8.4) 7.67d (8.5) 7.68d (8.5) 7.67d (8.3) 7.67d (8.5)
L-Ile 33 4.15mb 4.15mb 4.16mb 4.15mb 4.15mb
34 1.79md 1.80md 1.81m 1.80md 1.81md
35 0.81mf 0.82df (6.5) 0.83de (6.5) 0.81mf 0.83df (6.6)
36 1.31m, 1.20mi 1.31m, 1.20mi 1.32m, 1.20mh 1.31m, 1.20mi 1.32m, 1.20mi
37 0.78mf 0.78mf 0.79m 0.78mf 0.79mf
33-NH 8.23d (7.8) 8.25d (7.8) 8.27d (7.9) 8.25d (7.8) 8.24d (8.0)
(R )-E-OH-FA 39 4.98m 4.98m 4.98m 4.98m 4.98m
40 2.41m 2.40m 2.40m 2.40m 2.41m
42 1.55me 1.53me 1.56md 1.56me 1.54me
43 1.20mi 1.20mi 1.20mh 1.20mi 1.20mi
44 1.20mi 1.20mi 1.20mh 1.20mi 1.20mi
45 1.20mi 1.20mi 1.20mh 1.20mi 1.20mi
46 1.20mi 1.20mi 1.20mh 1.20mi 1.20mi
47 1.23mi, 1.07m 1.20mi 1.20mh 1.20mi 1.20mi
48 1.23mi 1.11m 1.20mh 1.20mi 1.20mi
49 0.81mf 1.44mh 1.11m 1.24mi, 1.08m 1.20mi
50 1.23mi 0.82df (6.5) 1.43mg 1.24mi 1.11m
51 0.81mf 0.82df (6.5) 0.83de (6.5) 0.81mf 1.43mh
52 0.83de (6.5) 1.24mi 0.83df (6.6)
53 0.81mf 0.83df (6.6)
a Compound 7, 600 MHz; 5, 6, 8, and 9, 400 MHz. b, c, d, e, f, g, h, i Overlapped in each column.
Table 3-1. 1H NMR Data for Compounds 5-9 in DMSO -d 6 a
G+J  in Hz)
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
moiety position
5 6 7 8 9
L-Glu 1 52.1 52.1 52.1 52.1 52.1
2 27.1 27.2 27.1 27.1 27.1
3 29.8 29.8 29.8 29.8 29.8
4 174 174 174.1 174 174
5 170.6 170.6 170.6 170.6 170.6
L-Leu2 6 51.6 51.6 51.6 51.6 51.6
7 39.5b 39.5b 39.5b 39.5b 39.5b
8 24.2c 24.2c 24.2c 24.2c 24.2c
9 23 23 23.1 23 23
10 22.9 22.9 22.9 22.9 22.9
11 171.8 171.8 171.8 171.8 171.7
D-Leu3 12 51.9 51.9 51.9 51.9 51.9
13 39.5b 39.5b 39.5b 39.5b 39.5b
14 24.2c 24.2c 24.2c 24.2c 24.2c
15 22.5 22.5 22.5 22.5 22.5
16 22.1 22.1 22.1 22.1 22.1
17 172.1d 172.1d 172.1d 172.1d 172.1d
L-Val 18 58.1 58.1 58.1 58.1 58.1
19 30.5 30.5 30.5 30.5 30.5
20 19.1 19.1 19.1 19.1 19.1
21 18 18 18 17.9 17.9
22 170.6 170.6 170.6 170.6 170.6
L-Asp 23 49.6 49.6 49.6 49.6 49.6
24 35.9f 36 36 35.9f 36
25 172.1d 172.1d 172.1d 172.1d 172.1d
26 169.9 169.9 169.9 169.8 169.8
D-Leu6 27 50.5 50.5 50.5 50.5 50.5
28 41.6 41.6 41.6 41.6 41.6
29 24.1c 24.1c 24.1c 24.1c 24.1c
30 21.9 21.9 21.9 21.8 21.8
31 21 21 21 21 21
32 171.6 171.6 171.6 171.6 171.6
L-Ile 33 56.5 56.5 56.5 56.5 56.5
34 35.8 35.8 35.8 35.7 35.7
35 15.5 15.5 15.5 15.4 15.4
36 24.5c 24.5c 24.5c 24.5c 24.5c
37 11 11.1 11.1 11 11
38 171 171 171 171 171
(R )-E-OH-FA 39 71.6 71.6 71.6 71.6 71.5
40 40.3 40.4 40.3 40.3 40.6
41 169.4 169.4 169.4 169.4 169.4
42 33.1 33.1 33.1 33.1 33.1
43 24.4c 24.4c 24.4c 24.3c 24.3c
44 29.2e 29.1e 29.3e 29.3e 29.2e
45 28.9e 28.8e 28.9e 28.9e 29.0e
46 28.6e 28.5e 28.8e 28.8e 28.8e
47 35.9f 26.7 28.5e 28.8e 28.8e
48 33.7 38.4 26.7 28.5e 28.5e
49 19 27.3 38.4 35.9f 26.7
50 26.3 22.5f 27.4 33.7 38.4
51 11.2 22.5f 22.5f 19 27.3
52 22.5f 26.4 22.4f
53 11.1 22.4f
a Compound 7, 150 MHz; 5, 6, 8, and 9, 100 MHz. b Overlapped with DMSO.
c,e Assignments may be interchanged in each column. d,f Overlapped in each column.
G C
Table 3-2. 13C NMR Chemical Shifts of Compounds 5-9 in DMSO -d 6 a
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Synergistic Actions of Compounds 5-9 with Bacillomycin D in an in vivo Cucumber 
Leaf-Disk Assay against Gray Mold Disease. The effects of compounds 5-9 on the 
suppressive activity of bacillomycin D were evaluated. The results are shown in Table 3-3 and 
Figure 3-4A. When administered singly, bacillomycin D (10, 15, and 20 PM) did not inhibit 
the development of gray mold disease on cucumber leaves. Compounds 5-9 (20 and 100 PM) 
also exhibited no inhibition of gray mold disease in cucumber leaves when administered alone,
suggesting that compounds 5-9 (20 and 100 PM) could neither inhibit the growth of B. 
cinerea directly nor induce the resistance of cucumber leaves to gray mold disease. However, 
the addition of compounds 5-9 (20 and 100 PM) to bacillomycin D (10, 15, and 20 PM) 
significantly enhanced the effect of bacillomycin D activity in the in vivo assay, indicating 
that compounds 5-9 have synergistic activities with bacillomycin D under this condition. The 
inhibition rates of compounds 5-9 (100 PM) with bacillomycin D (10 PM) were 26.8, 51.2,
78.7, 81.7, and 66.5%, indicating that the C14 and C15 [Ile7]surfactins were more active than 
the C13 [Ile7]surfactins. Although these data could not fully explain the suppressive activity 
gap between the culture supernatant and bacillomycin D in it, they clearly demonstrated that 
the [Ile7]surfactin homologues enhance the suppressive activity of bacillomycin D against
gray mold disease and can partially close the gap.
To examine the mechanism underlying the synergism of the [Ile7]surfactin homologues
with bacillomycin D, a mycelial growth inhibition assay and a conidial germination inhibition 
assay using B. cinerea were performed in vitro (Figures 3-4B and C). In the mycelial growth 
inhibition assay, no significant difference between Eobs and Eexp was observed, and thus the 
effect of compound 7 on the activity of bacillomycin D was additive (Figure 3-4B). In the 
conidial germination inhibition assay, the addition of 20 PM of compound 7 to 4 PM of 
bacillomycin D did not enhance the activity of bacillomycin D (Figure 3-4C). Finally, I
observed stereomicroscopically the inoculated parts in the cucumber leaf-disk assay (Figure 
3-4D). The synergistic activity to the disease was observed in the condition 20 PM of 
compound 7 with 20 PM of bacillomycin D although mycelial growth of B. cinerea was 
apparently normal in the same condition. These data suggested that the synergistic action of 
[Ile7]surfactin and bacillomycin D do not interfere with the mycelial growth and conidial 
germination of the gray mold, but rather might inhibit infection processes such as 
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appressorium formation and penetration into the host.
The present study has shed light on a novel role of [Ile7]surfactin homologues in the 
biological control system of strain SD-32, namely, the compounds were shown to work 
synergistically with bacillomycin D in controlling gray mold disease under natural conditions,
and this synergism may be particularly important for inhibiting the infection process of gray 
mold in cucumber leaves. Surfactin family lipodepsipeptides are well-known to act as potent 
surface-active compounds and antibiotics against a number of bacteria and phytopathogenic 
fungi.11 In addition, recent investigations have illustrated a number of other diverse activities 
for these compounds, including roles in the induction of plant resistance or the mechanism of 
biofilm formation as part of the biological control system of Bacillus species.12
It has been reported that B. amyloliquefaciens produces a wide variety of bioactive 
metabolites such as polyketides (bacillaenes, difficidin, oxidifficidin, and macrolactins),13,14
siderophore (bacillibactin),15 non-ribosormally synthesized lipopeptides and lipodepsipeptides 
(bacillomycin D, surfactins, and fengycins or plipastatins),16 and ribosomally synthesized 
peptides (plantazolicins).17 However, literatures with respect to interactions of each metabolite 
are limited.
Many Bacillus strains have been reported to produce surfactin and bacillomycin D 
simultaneously,16,18-21 but the interaction of bacillomycin D and surfactin has not been studied. 
In contrast, several researchers have focused on the interactions of standard surfactin and 
iturin A.22-24 Bacillomycin D belongs to the iturin class lipopeptides, and bacillomycin D 
(Asn-Tyr-Asn-Pro-Glu-Ser-Thr-E-AA) and iturin A (Asn-Tyr-Asn-Gln-Pro-Asn-Ser-E-AA) 
have closely related structures.12 Hiraoka et al.22 showed that B. subtilis RB14 produced both 
standard surfactin and iturin A, and that the standard surfactin could enhance the in vitro
activity of iturin A against Fusarium oxysporum. They discussed the importance of the 
structural similarities between surfactin and iturin A in their synergism. Thimon et al.23
reported that the antifungal activity of iturin A against Saccharomyces cerevisiae in vitro was 
enhanced in the presence of standard surfactin and that this effect was clear at a subinhibitory 
concentration of iturin A. Their results are in agreement with mine from the point of view of 
the necessary concentration although I found their synergism not in vivo but in vitro. A
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mechanism for the antibiotic action of bacillomycin D and the other lipopeptides has been 
proposed.24-26 Lipopeptide molecules penetrate the cytoplasmic membrane of the target cell
and form oligomeric structures (lipopeptide aggregates) that are ion-conducting. Maget-Dana 
et al.27 stated that the marked surfactant properties of surfactin helped iturin A to reach and 
disrupt the membrane of the target cells. In my experiment, however, the synergistic action of 
[Ile7]surfactin and bacillomycin D was not observed with respect to in vitro mycelial growth 
or the conidial germination inhibition assays. These data clearly suggest that the synergistic 
actions of [Ile7]surfactin and bacillomycin D were different from those of surfactin and iturin 
A. The difference is presumably due to structural difference between bacillomycin D and 
iturin A, and/or [Ile7]surfactin and standard surfactin.
The detailed mechanism by which [Ile7]surfactin homologues enhanced the suppressive 
effect of bacillomycin D in the cucumber leaf-disk assay is still unknown and remains to be 
studied.
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Figure 3-4. In vivo and in vitro assay of compounds 5-9 with bacillomycin D against B.
cinerea. (A) In vivo assay of compound 5-9 with bacillomycin D using cucumber 
cotyledon and B. cinerea (n = 4). Bac D indicates anteiso-C17 bacillomycin D. 
Gray mold disease was completely inhibited on the leaves in the dashed box. (B) 
Mycelial growth inhibition assay of compound 7 with bacillomycin D in vitro (n =
3). (C) Conidial germination inhibition assay of compound 7 with bacillomycin D 
in vitro (n = 3). (D) Stereomicroscope observation of in vivo assay of compound 7
with anteiso-C17 bacillomycin D. Scale bar indicates 2 mm. (a), Infection zone of 
B. cinerea; (b), Mycelial growth of B. cinerea.
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Chapter 4
Conclusion
Two new cyclic lipopeptides (3 and 4) and two new cyclic lipodepsipeptides (5 and 6) were 
isolated from the culture supernatant of B. amyloliquefaciens biocontrol strain SD-32, 
together with five known metabolites, iso-C15 (1), iso-C16 bacillomycin D (2), iso-C14 (7), 
anteiso-C15 (8), and iso-C15 [Ile7]surfactin (9). Spectroscopic and chemical analyses of the 
new compounds 3-6 revealed their structures to be anteiso-C17 bacillomycin D (3), iso-C17
bacillomycin D (4), anteiso-C13 [Ile7]surfactin (5), and iso-C13 [Ile7]surfactin (6), 
respectively.
The activities of bacillomycin D homologues (1-4) were evaluated against 13 plant 
pathogens in the in vitro assay: the activities of anteiso- and iso-C17 bacillomycin D (3 and 4)
were almost the same of each other, and stronger than those of iso-C15 and iso-C16
bacillomycin D (1 and 2); the activities of iso-C15 bacillomycin D (1) were the weakest.
Compounds 1-4 inhibited the growth of all fungi tested. Furthermore, compounds 1-4 at 
concentrations of 80, 40, 30, and 30 PM, respectively, completely inhibited the Botrytis
cinerea infection in cucumber leaves. However, Pythium aphanidermatum was not inhibited 
at all by any of the compounds.
By contrast, the activities of [Ile7]surfactin homologues (5-9) in the in vitro assay were 
much lower than those of bacillomycin D homologues; however, [Ile7]surfactin homologues 
(5-9) clearly showed synergistic activities with bacillomycin D in the in vivo assay using 
cucumber cotyledon and B. cinerea. The synergistic effects of [Ile7]surfactin homologues to
bacillomycin D against B. cinerea were not observed in the in vitro mycelial growth or
conidial germination inhibition assays, implying that these effects might play a role in the 
gray mold infection of cucumber leaves.
Based on these results, I conclude the following.
1) B. amyloliquefaciens biocontrol strain SD-32 produces bacillomycin D homologues and 
[Ile7]surfactin homologues.
2) Bacillomycin D homologues have antifungal activity and play an important role in the 
biological control by B. amyloliquefaciens SD-32.
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3) The strain SD-32 is unique because it produces a higher content of powerful C17
bacillomycin D homologues than other strains reported previously.
4) [Ile7]surfactin homologues enhance the activities of bacillomycin D homologues under
actual conditions.
The detailed mechanism by which [Ile7]surfactin homologues enhanced the suppressive 
effect of bacillomycin D in the in vivo assay is still unknown and remains to be studied. In 
addition, the data shown in this study could not completely explain the suppressive activity 
gap between the culture supernatant on the one hand and bacillomycin D and the 
[Ile7]surfactin homologues in it on the other. This indicates the presence of metabolite(s) that
contribute to gray mold disease suppression other than bacillomycin D and [Ile7]surfactin
homologues. Therefore, research to identify the relevant factors other than bacillomycin D
and [Ile7]surfactin homologues is needed.
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Summary
Botrytis cinerea Pers. Fr. is a pathogen that causes gray mold disease in many crops and 
causes serious crop losses worldwide. Although chemical fungicides have been used for many 
years to control the pathogen, the ability of B. cinerea to adapt quickly to new chemicals by
developing resistance creates the need for continuous development of new fungicides. With 
increasing concern over fungicide resistance and over the environmental impact and food 
safety of chemical fungicides, biological control has attracted considerable attention.
To develop new and effective biological control agents against gray mold disease, a
screening search was performed, and Bacillus amyloliquefaciens SD-32 was isolated from soil 
in Japan as a promising and effective agent against gray mold disease. To gain insight into the 
mechanisms responsible for the biological control achieved by B. amyloliquefaciens strain 
SD-32, in this study, attempts were made to identify the factors produced by the bacterium 
that contribute to the control of gray mold disease and to clarify the role of these factors in the 
biological control system.
Using an in vitro antifungal-activity-guided purification, two new cyclic lipopeptides (3
and 4) were isolated from the culture supernatant of B. amyloliquefaciens strain SD-32, 
together with two known metabolites, iso-C15 and iso-C16 bacillomycin D (1 and 2). 
Spectroscopic and chemical analyses identified the structures of the new compounds 3 and 4
as anteiso-C17 bacillomycin D and iso-C17 bacillomycin D, respectively. The activities of 
compounds 1-4 were evaluated against 13 plant pathogens: compounds 1-4 inhibited the 
growth of all fungi tested. The activities of anteiso- and iso-C17 bacillomycin D (3 and 4)
were almost the same of each other, and stronger than those of iso-C15 and iso-C16
bacillomycin D (1 and 2); the activities of iso-C15 bacillomycin D (1) were the weakest. 
Furthermore, compounds 1-4 at concentrations of 80, 40, 30, and 30 PM, respectively, 
completely inhibited B. cinerea infection in cucumber leaves.
The activity of the culture supernatant, however, was not ascribed exclusively to
bacillomycin D homologues; therefore, metabolites other than bacillomycin D were also 
investigated. After purifying the fractions that exhibited synergistic activity with bacillomycin 
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D, two new cyclic lipodepsipeptides (5 and 6) were found in the culture supernatant of this 
strain, together with three known metabolites, iso-C14, anteiso-C15, and iso-C15 [Ile7]surfactin
(7, 8, and 9). Spectroscopic and chemical analyses identified the structures of the new 
compounds 5 and 6 as anteiso-C13 and iso-C13 [Ile7]surfactin, respectively. Interestingly, 
[Ile7]surfactin homologues significantly enhanced the suppressive effect of bacillomycin D
against B. cinerea in an in vivo cucumber leaf-disk assay, although they showed no 
suppressive effect by themselves, suggesting that synergistic actions between the 
[Ile7]surfactin homologues and bacillomycin D were involved in the suppression of gray mold 
disease by the bacterium. Furthermore, the synergistic effects were not observed in in vitro
mycelial growth or conidial germination inhibition assays, implying that these effects might 
play a role in gray mold infection in cucumber leaves.
Based on these results, I conclude the following.
1) B. amyloliquefaciens biocontrol strain SD-32 produces bacillomycin D homologues and 
[Ile7]surfactin homologues.
2) Bacillomycin D homologues have antifungal activity and play an important role in the 
biological control by B. amyloliquefaciens SD-32.
3) The strain SD-32 is unique because it produces a higher content of powerful C17
bacillomycin D homologues than other strains reported previously.
4) [Ile7]surfactin homologues enhance the activities of bacillomycin D homologues under
actual conditions.
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᦬せ
㻌
Botrytis cinerea Pers. Fr. 䛿ከ䛟䛾స≀䛾⅊Ⰽ䛛䜃⑓䛾ཎᅉ䛸䛺䜛᳜≀⑓ཎ⳦䛷䛒䜛䚹ᮏ
⳦䜢㜵㝖䛩䜛䛯䜑䠈㛗ᖺ䛻䜟䛯䜚໬Ꮫྜᡂ㎰⸆䛜౑⏝䛥䜜䛶䛝䛯䛜䠈໬Ꮫྜᡂ㎰⸆⪏ᛶ⳦
䛾ฟ⌧䛻䜘䜚䠈ᖖ䛻᪂䛧䛔స⏝≉ᛶ䜢᭷䛩䜛໬Ꮫྜᡂ㎰⸆䛾◊✲㛤Ⓨ䛜ồ䜑䜙䜜䠈䛣䜜䛻኱
䛝䛺䝁䝇䝖䛜๭䛛䜜䛶䛔䜛䚹᳜≀⑓ཎ⳦䛾⸆๣⪏ᛶၥ㢟䛻ຍ䛘䠈໬Ꮫྜᡂ㎰⸆䛾⎔ቃ䛻୚䛘
䜛ᙳ㡪䜔㣗ᩱ䛾Ᏻ඲ᛶ䛾ၥ㢟➼䛛䜙䠈໬Ꮫྜᡂ㎰⸆䛾䜏䛻㢗䛳䛯᳜≀⑓ᐖ㜵㝖䛻␲ၥ➢
䛜௜䛟≧ἣ䛾୰䠈໬Ꮫྜᡂ㎰⸆䛻௦䜟䜛㑅ᢥᯞ䛸䛧䛶䠈⏕≀㎰⸆䜈䛾ᮇᚅ䛜㧗䜎䛳䛶䛔䜛䚹㻌
䛣䛾䜘䛖䛺⫼ᬒ䛾䜒䛸䚸⅊Ⰽ䛛䜃⑓䛻ᑐ䛩䜛ຠᯝ䛾㧗䛔㜵㝖ຠᯝ䜢᭷䛩䜛⳦ᰴ䜢᥈⣴䛧䛯
䛸䛣䜝䠈㠀ᖖ䛻㧗䛔㜵㝖ຠᯝ䜢♧䛩 Bacillus amyloliquefaciens SD-32ᰴ䜢ぢฟ䛧䛯䚹ᮏ◊✲
䛷䛿䠈ᮏ⳦ᰴ䛾㜵㝖ຠᯝ䛾䝯䜹䝙䝈䝮䜢ゎ᫂䛩䜛䛯䜑䠈⅊Ⰽ䛛䜃⑓㜵㝖䛻㛵䜟䜛௦ㅰ⏘≀䜢
༢㞳䞉⢭〇䛧䠈䛭䛾ᙺ๭䜢᫂䜙䛛䛻䛩䜛䛣䛸䜢┠ⓗ䛸䛧䛯䚹㻌
ᮏ⳦䛾ᇵ㣴ୖΎ䛛䜙䠈PDA 䝥䝺䞊䝖ୖ䛷䛾⅊Ⰽ䛛䜃⑓⳦䛻ᑐ䛩䜛άᛶ䜢ᣦᶆ䛻䛧䛶άᛶ
≀㉁䛾༢㞳䜢ヨ䜏䛯䚹䛭䛾⤖ᯝ䠈໬ྜ≀ 1-4 䜢༢㞳䛧䠈2D-NMR, MALDI-TOF-MS/MS, ໬
Ꮫศᯒ䛻䜘䜚䠈䛭䛾ᵓ㐀䜢䠈䛭䜜䛮䜜 iso-C15, iso-C16, anteiso-C17, iso-C17 bacillomycin D 䛸
ྠᐃ䛧䛯䚹1䛚䜘䜃 2䛿᪤▱໬ྜ≀䛷䛒䛳䛯䛜䠈3ཬ䜃 4䛿᪂つ໬ྜ≀䛷䛒䛳䛯䚹㻌
໬ྜ≀ 1-4䛾ྛ✀᳜≀⑓ཎ⳦䛻ᑐ䛩䜛ຠᯝ䜢 㻼㻰㻭䝥䝺䞊䝖ୖ䛷ㄪ䜉䛯䛸䛣䜝䠈໬ྜ≀ 1-4
䛿䠈㻌 12 ✀䛾᳜≀⑓ཎ⳦䛻ᑐ䛧䛶⏕⫱㜼ᐖຠᯝ䜢♧䛧䠈䛭䛾ຠᯝ䛿 anteiso-C17, iso-C17
bacillomycin D 䠄3, 4䠅䛜᭱䜒ᙉ䛟䠈ḟ䛔䛷 iso-C16 bacillomycin D 䠄2䠅, iso-C15 bacillomycin 
D 䠄1䠅 䛜᭱䜒ᙅ䛛䛳䛯䚹䛥䜙䛻䠈䛣䜜䜙䛾໬ྜ≀䛾⅊Ⰽ䛛䜃⑓䛻ᑐ䛩䜛ຠᯝ䜢䜻䝳䜴䝸Ꮚⴥ䜢
⏝䛔䛯䝸䞊䝣䝕䜱䝇䜽ヨ㦂䛷ㄪ䜉䛯䛸䛣䜝䠈໬ྜ≀ 1-4 䠄䛭䜜䛮䜜 80, 40, 30, 30PM䠅䛿䠈Ꮚⴥ
ୖ䛷⅊Ⰽ䛛䜃⑓䛾Ⓨ⑓䜢᏶඲䛻ᢚไ䛧䛯䚹㻌
㻌 䛥䜙䛺䜛᳨ウ䛾㐣⛬䛷䠈ᮏ⳦䛾ᇵ㣴ୖΎ䛾⅊Ⰽ䛛䜃⑓䛻ᑐ䛩䜛άᛶ䛿䚸bacillomycin D 䝩
䝰䝻䜾䛾άᛶ䛰䛡䛷䛿ㄝ᫂䛷䛝䛺䛔䛣䛸䛜᫂䜙䛛䛸䛺䛳䛯䚹䛭䛣䛷䠈bacillomycin D 䛻ᑐ䛩䜛
┦஌ຠᯝ䜢ᣦᶆ䛻άᛶ⏬ศ䛾⢭〇䜢⾜䛖䛣䛸䛷䠈໬ྜ≀ 5-9 䜢༢㞳䛧䠈2D-NMR,
MALDI-TOF-MS/MS, ໬Ꮫศᯒ䛻䜘䜚䠈䛭䛾ᵓ㐀䜢䠈䛭䜜䛮䜜 anteiso-C13, iso-C13, iso-C14,
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anteiso-C15, iso-C15 [Ile7]surfactin 䛸ྠᐃ䛧䛯䚹7-9䛿᪤▱໬ྜ≀䛷䛒䛳䛯䛜䠈5䛚䜘䜃 6䛿᪂
つ໬ྜ≀䛷䛒䛳䛯䚹㻌
⯆࿡῝䛔䛣䛸䛻䠈[Ile7]surfactin 䝩䝰䝻䜾䛿䠈䜻䝳䜴䝸Ꮚⴥ䜢⏝䛔䛯䝸䞊䝣䝕䜱䝇䜽ヨ㦂䛻䛚䛔
䛶䠈䛭䜜⮬㌟䛿άᛶ䜢ᣢ䛯䛺䛔䛻䜒䛛䛛䜟䜙䛪䠈bacillomycin D䝩䝰䝻䜾䛾άᛶ䜢ቑ኱䛥䛫䜛
ᶵ⬟䜢᭷䛧䛶䛚䜚䠈䛭䛾ຠᯝ䛿ᮏ⳦䛾⅊Ⰽ䛛䜃⑓䛾ᢚไຠᯝ䛻㛵୚䛧䛶䛔䜛䛣䛸䛜♧၀䛥䜜
䛯䚹䛥䜙䛻䠈in vitro 䛻䛚䛡䜛⳦⣒ᡂ㛗㜼ᐖヨ㦂䞉⬊ᏊⓎⱆ㜼ᐖヨ㦂䛻䛚䛔䛶䠈[Ile7]surfactin
䝩䝰䝻䜾䛸bacillomycin D䝩䝰䝻䜾䛾┦஌ຠᯝ䛿ㄆ䜑䜙䜜䛪䠈䜻䝳䜴䝸Ꮚⴥ䜢⏝䛔䛯䝸䞊䝣䝕䜱
䝇䜽ヨ㦂䛷ㄆ䜑䜙䜜䜛┦஌ຠᯝ䛿䠈⅊Ⰽ䛛䜃⑓⳦䛾䜻䝳䜴䝸䛻ᑐ䛩䜛ឤᰁ㐣⛬䜢㜼ᐖ䛧䛶䛔
䜛䛣䛸䛜♧၀䛥䜜䛯䚹㻌
㻌
㻌
㻌
㻌
㻌
㻌
㻌
㻌
㻌
㻌
㻌
㻌
㻌
㻌
㻌
㻌
㻌
㻌
63 
 
㻌
List of Publications
1. Tanaka, K.; Ishihara, A.; Nakajima, H. Isolation of anteiso-C17, iso-C17, iso-C16, and 
iso-C15 bacillomycin D from Bacillus amyloliquefaciens SD-32 and their antifungal 
activities against plant pathogens. J. Agric. Food Chem. 2014, 62, 1469-1476. (Chapter 2)
2. Tanaka, K.; Amaki, Y.; Ishihara, A.; Nakajima, H. Synergistic effects of [Ile7]surfactin 
homologues with bacillomycin D in suppression of gray mold disease by Bacillus 
amyloliquefaciens biocontrol strain SD-32. J. Agric. Food Chem. 2015, 63, 5344–5353.
(Chapter 3)





















